Type 2 Diabetes Mellitus and Chronic Kidney Disease

Browse trials for

• Kidney Diseases 3,840
• Renal Insufficiency, Chronic 3,144
• Diabetes Mellitus 10,925
• Diabetes Mellitus, Type 2 9,359

Kidney Diseases

3,840 studies on the registry are indexed under Kidney Diseases; 500 are open to participants now.

This study's enrollment of 150 is below the median of 192 across 1,033 observational studies indexed under Kidney Diseases.

Lead sponsor

Sohag University is the lead sponsor of 1,183 studies on the registry; 612 are open to participants now.

Study population

Groups and cohorts

• Co existance of diabetes mellitus and chronic kidney disease

  Study basic coagulation profile and platelet indices among those patients with combined diabetes mellitus and chronic kidney disease

  Diagnostic Test: Hematologic tests for patients with diabetes mellitus and chronic kidney disease

• Diabetes mellitus without chronic kidney disease

  Study basic coagulation profile and platelet indices among those patients with diabetes mellitus only

  Diagnostic Test: Hematologic tests for patients with diabetes mellitus and chronic kidney disease

• Chronic kidney disease without diabetes mellitus

  Study basic coagulation profile and platelet indices among those patients with chronic kidney disease without diabetes mellitus

  Diagnostic Test: Hematologic tests for patients with diabetes mellitus and chronic kidney disease

Interventions

• Diagnostic testHematologic tests for patients with diabetes mellitus and chronic kidney disease

  Study basic coagulation profile and platelet indices among diabetic patients with chronic kidney disease

Primary outcomes

1. Estimate risk of thrombosis or bleeding for the 3 study groups by prothrombin time

   We will include 150 patients and classify them into 3 groups each one consists of 50 patients First group those patients with diabetes mellitus only Second group those patients with chronic kidney disease only Third group those patients with combined diabetes mellitus type 2 and chronic kidney disease not on hemodialysis First we will measure prothrombin time

   Time frame: 1 day

2. Estimate risk of thrombosis or bleeding for the 3 study groups by prothrombin concentration

   We will include 150 patients classified into 3 groups as previous Second measure is prothrombin concentration

   Time frame: 1 day

3. Estimate risk of thrombosis or bleeding for the 3 study groups by INR

   We will include 150 patients as previous Third measure is INR ( international normalised ratio )

   Time frame: 1 day

4. Estimate risk of thrombosis or bleeding for the 3 study groups by partial thromboplastin time

   We will include 150 patients as previous Fourth measure is partial thromboplastin time

   Time frame: 1 day

5. Estimate risk of thrombosis or bleeding for the 3 study groups by serum fibrinogen

   We will include 150 patients as previous Fifth measure is serum fibrinogen level in the 3 groups

   Time frame: 1 day

6. Estimate risk of thrombosis or bleeding for the 3 study groups by mean platelet volume

   We will include 150 patients as previous Sixth measure is mean platelet volume in the 3 groups

   Time frame: 1 day

7. Estimate risk of thrombosis or bleeding for the 3 study groups by platelet distribution width

   We will include 150 patients as previous Seventh measure is platelet distribution width for the 3 groups

   Time frame: 1 day

8. Estimate risk of thrombosis or bleeding for the 3 study groups by plateletcrit

   We will include 150 patients as previous Eighth measure is plateletcrit of the 3 study groups

   Time frame: 1 day

Publications

• Gundogan K, Bayram F, Capak M, Tanriverdi F, Karaman A, Ozturk A, Altunbas H, Gokce C, Kalkan A, Yazici C. Prevalence of metabolic syndrome in the Mediterranean region of Turkey: evaluation of hypertension, diabetes mellitus, obesity, and dyslipidemia. Metab Syndr Relat Disord. 2009 Oct;7(5):427-34. doi: 10.1089/met.2008.0068. PubMed 19754305 ↗
• Odegaard AO, Jacobs DR Jr, Sanchez OA, Goff DC Jr, Reiner AP, Gross MD. Oxidative stress, inflammation, endothelial dysfunction and incidence of type 2 diabetes. Cardiovasc Diabetol. 2016 Mar 24;15:51. doi: 10.1186/s12933-016-0369-6. PubMed 27013319 ↗
• Ulutas KT, Dokuyucu R, Sefil F, Yengil E, Sumbul AT, Rizaoglu H, Ustun I, Yula E, Sabuncu T, Gokce C. Evaluation of mean platelet volume in patients with type 2 diabetes mellitus and blood glucose regulation: a marker for atherosclerosis? Int J Clin Exp Med. 2014 Apr 15;7(4):955-61. eCollection 2014. PubMed 24955167 ↗

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Sap, Icf, Csr, Analytic code